Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q02548
UPID:
PAX5_HUMAN
Alternative names:
B-cell-specific transcription factor
Alternative UPACC:
Q02548; A3QVP6; A3QVP7; A3QVP8; C0KTF6; C0KTF7; C0KTF8; C0KTF9; C0KTG0; O75933; Q5SFM2; Q6S728; Q6S729; Q6S730; Q6S731; Q6S732
Background:
Paired box protein Pax-5, also known as B-cell-specific transcription factor, is pivotal in the development of B-lymphocytes. It regulates the transition of lymphoid progenitors to the B-cell lineage by repressing inappropriate genes while activating specific ones, thus influencing cell adhesion, migration, and the maturation of B-cells. Additionally, Pax-5 plays a crucial role in maintaining Epstein-Barr virus genome copy number and inhibiting lytic reactivation.
Therapeutic significance:
Given its essential role in B-cell development and its association with acute lymphoblastic leukemia, a common childhood malignancy, Pax-5 presents a promising target for therapeutic intervention. Understanding the role of Paired box protein Pax-5 could open doors to potential therapeutic strategies, especially in the context of leukemia and viral infections.